Patent examination ongoing in Korea, USA, Europe, China, India etc.
Bukwang Pharmaceutical (“Bukwang”) announced that its subsidiary, Dyna Therapeutics (“Dyna”) registered composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to Japan Patent Office on 21st July 2020. With registration of this patent, the composition of SOL-804 will be protected until 2035 in Japan. Additionally, the patent application is currently under examination in various countries, including Korea, USA, Europe, China, India, Eurasia and others.
![]()
Dyna is Bukwang’s 100% owned subsidiary which was established to focus on drug delivery and formulation. Dyna obtained exclusive global rights for the development and commercialization of SOL-804 from a Danish company, Solural Pharma, in 2016.
SOL-804 is a improved and proprietary formulated version of currently available drug for the treatment of metastatic castration-resistant prostate cancer. The proprietary formulation removes food effect and allow administration of lower dose hence SOL-804 is expected to increase patient compliance and safety profile. The phase 1 clinical study of SOL-804 in cancer patients that allow pharmacodynamic evaluation is currently under preparation.
Bukwang representative said “the registration of SOL-804’s patent in Japan acknowledges the innovative value of the technology and is an important step to advance the program into the global market.” |